Drug Discovery World

MARCH 16, 2023

in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The financing will enable the company to launch Iktos Robotics; a drug discovery platform which combines artificial intelligence and automation of chemical synthesis. appeared first on Drug Discovery World (DDW).

Drugs 130

Drugs Clinical Development Pharmaceuticals Research 130

Drug Discovery World

JUNE 27, 2023

It will be headquartered at the Monash Institute of Pharmaceutical Sciences (MIPS). Together, the three institutions, in collaboration with Therapeutic Innovation Australia (TIA), will guide early-stage projects through the process of identifying drug candidates with potential commercial value. MedChem Australia will fill this gap.

Drugs 130

Drugs Medical Chemistry Pharmacokinetics Science 130

Drug Discovery World

MAY 25, 2023

Broughton: new inhalation testing service The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. The post The latest drug discovery product launches appeared first on Drug Discovery World (DDW).

Production 130

Production DNA Assay Development Drugs 130

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Hunter

JUNE 5, 2023

Macrocyclic molecules, containing 12 or more atoms in a ring system, are increasingly prevalent in drug discovery, with over 67 macrocyclic drugs approved so far and several notable examples of clinical success highlighted on Drug Hunter recently, including MK-0616 , repotrectinib , and pacritinib.

Process Chemistry 206

Process Chemistry Drugs Production Clinical Development 206

Drug Discovery World

NOVEMBER 22, 2022

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals. . The post Academic-industry collaboration extends cancer drug discovery alliance appeared first on Drug Discovery World (DDW).

Drugs 130

Drugs Engineering Clinical Development Research 130

Drug Discovery World

JULY 2, 2024

This article will examine the regional focus of the country’s life sciences industry, its infrastructure of bioparks, and how this foundation ensures Switzerland maintains its role as a global leader in drug discovery. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

MARCH 7, 2023

For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. Here at FAB our proprietary approach aims to overcome this fundamental challenge to human health as we work to discover and develop new drugs for age-associated diseases.”

International 246

International Science Pharmaceuticals DNA 246

Drug Discovery World

DECEMBER 15, 2022

PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership. . PrecisionLife analyses multi-modal datasets including genomic, clinical, and epidemiological data to accurately stratify patients and understand subgroup-relevant disease risks and drivers. .

Clinical Trials 130

Clinical Trials Pharmaceuticals Clinical Development Trials 130

Drug Discovery World

FEBRUARY 28, 2023

Dr Asma Patel , Vice President of Integrated Services for Early Development at Quotient Sciences, reflects on the biggest barriers to rare disease drug development and how companies can overcome these. Utilising an integrated approach for development can improve the likelihood of downstream clinical and commercial success.

Drug Development 130

Drug Development Disease Drugs Production 130

Drug Discovery World

AUGUST 4, 2023

“…a truly differentiated broad-spectrum drug that can tackle the toughest drug-resistant superbugs.” ” The announcement follows a report by University of Queensland researchers, which warned a global crisis of antibiotic resistance is inevitable , despite promising developments in new antibiotics.

Clinical Development 130

Clinical Development Hospitals Research Pharmaceuticals 130

Drug Discovery World

FEBRUARY 12, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

JANUARY 16, 2024

The company was initially founded as partnership between three research organisations, Cambridge University, Imperial College London and University College London, and three pharmaceutical companies, AstraZeneca, GSK and J&J. “We

Pharmaceutical Companies 130

Pharmaceutical Companies Clinical Development Pharmaceuticals Disease 130

The Pharma Data

NOVEMBER 29, 2020

(HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that Melissa Palmer , MD, an internationally renowned Hepatologist, will join the Company as Chief Medical Officer, effective December 1, 2020. Wu , Founder, Chairman and CEO of Ascletis. ” About Ascletis.

Clinical Development 40

Clinical Development Disease Clinical Trials Pharmaceutical Companies 40

Drug Discovery World

JUNE 21, 2023

Citius Pharmaceuticals has revealed positive results from its Phase IIb Study of Halo-Lido (CITI-002) for the treatment of haemorrhoids. Following the 21 st Century Cures Act, higher emphasis is placed on using Patient Reported Outcome (PRO) instruments in clinical trials.

Treatment 130

Treatment Trials Clinical Trials Clinical Development 130

Drug Discovery World

JANUARY 5, 2023

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School. .

Therapies 130

Therapies Medical Schools Clinical Development Pharmaceuticals 130

The Premier Consulting Blog

AUGUST 21, 2024

As clinical development of an investigational product proceeds, Sponsors often conduct global clinical trials which require preparation of content to support dossiers in multiple geographies, meeting the regulatory requirements of each region. Drug substance content in Module 3.2.S P) is per the specific IMPD guidance.

Clinical Development 52

Clinical Development Pharmaceuticals Clinical Trials Trials 52

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. This means that we are not doing something right.

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

Drug Discovery World

SEPTEMBER 14, 2023

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. In July 2023, AstraZeneca and Ionis Pharmaceuticals expanded their existing collaboration on eplontersen to also include Latin America. billion, a decrease of $15.0 Chris Boshoff, M.D.,

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Drug Discovery World

JANUARY 6, 2023

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer. . The post $5 million to fund trial of immunotherapy for uveal melanoma appeared first on Drug Discovery World (DDW).

Trials 130

Trials Clinical Development Pharmaceuticals Therapies 130

Drug Discovery World

DECEMBER 13, 2023

A Phase II clinical trial of FR104/VEL-101 in patients undergoing kidney transplantation is under preparation by OSE’s partner Veloxis Pharmaceuticals. In the FIRsT Phase I/II clinical trial, seven patients completed one-year treatment with FR104/VEL-101 and one is ongoing (Month 4).

Clinical Trials 130

Clinical Trials Hospitals Trials Clinical Development 130

Drug Discovery World

FEBRUARY 16, 2023

There have been a number of significant appointments in the drug discovery sector over the last month. The post February’s key industry appointments appeared first on Drug Discovery World (DDW). So who are the latest movers and shakers?

Small Molecule 130

Small Molecule Pharmaceuticals Clinical Development Science 130

Cytel

APRIL 10, 2024

Orphan drug designation is a regulatory status granted to pharmaceuticals developed for the treatment of rare diseases. It provides incentives to encourage the research, development, and approval of therapies targeting small patient populations.

Disease 59

Disease Drugs Pharmaceuticals Therapies 59

Conversations in Drug Development Trends

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. At Worldwide, we understand that every program is different, which means every drug development path forward will be unique.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Drug Discovery World

JANUARY 10, 2024

The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications.

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Research Clinical Development Drug Development 98

DrugBank

JUNE 6, 2024

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.

Drug Development 75

Drug Development Clinical Trials Drugs Therapies 75

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

Cytel

MAY 7, 2024

Market exclusivity for orphan drugs traces back to the early 1980s in the United States, with the landmark Orphan Drug Act of 1983. This was a turning point, igniting a wave of research and development into treatments for rare diseases that had previously been neglected.

Marketing 59

Marketing Production Drugs Disease 59

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. With 3,633 advanced therapeutical medicinal products (ATMPs) currently in some form of clinical or pre- clinical development, the sector shows no signs of slowing down.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

FDA Law Blog: Biosimilars

AUGUST 8, 2023

Lewis, Senior Regulatory Device & Biologics Expert — Please sing to the tune of “ Honesty ,” by Billy Joel: Nitrosamines, it’s such an ugly word, In pharmaceuticals’ impurity. Nitrosamines are hardly ever good, Now FDA has issued policy. In other words, it’s a sweeping application across the industry.

FDA 74

FDA Organic Chemistry Drugs Production 74

The Pharma Data

SEPTEMBER 29, 2021

The new FIND-CKD study extends our clinical research for finerenone to a non-diabetic population where the unmet need is high for brand spanking new treatments to delay disease progression.”. Food and Drug Administration (FDA) supported the positive results of the FIDELIO-DKD phase III clinical trial study for patients with CKD and T2D.

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. executive vice president of research and development. “The executive vice president of research and development. “We THE WOODLANDS, Texas, Dec.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Drug Discovery World

MAY 3, 2023

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction. Vicore Pharma states that results from the trial are expected in Q4, 2023.

FDA Approval 130

FDA Approval Trials Pharmaceutical Companies Disease 130

Sygnature Discovery

JANUARY 26, 2024

Here at Sygnature Discovery, we offer specialised expertise in early-stage drug formulation. Leveraging years of experience, we efficiently advance your compounds through preclinical studies and reduce risks as you move into clinical development.

Process Chemistry 52

Process Chemistry Pharmacokinetics Clinical Development Laboratories 52

The Pharma Data

DECEMBER 16, 2020

17, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. OS is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. About CNS Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52